Stephen Leong
University of Colorado Cancer Center · 157 works · 6,132 citations · h-index 28
Top works
- Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
- Patient-derived tumour xenografts as models for oncology drug development
- Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- Esophageal and Esophagogastric Junction Cancers, Version 1.2015
- Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
- A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors
- Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K- ras –Mutated Colorectal Cancer
- Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development
- Metaanalysis of Survival, Complications, and Imaging Response following Chemotherapy-based Transarterial Therapy in Patients with Unresectable Intrahepatic Cholangiocarcinoma
- Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer
- Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models
- From Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
- Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies
- Multidisciplinary management for esophageal and gastric cancer
- Pilot Prehabilitation Program for Patients With Esophageal Cancer During Neoadjuvant Therapy and Surgery
- OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
- The Insulin-like Growth Factor I Receptor/Insulin Receptor Tyrosine Kinase Inhibitor PQIP Exhibits Enhanced Antitumor Effects in Combination with Chemotherapy Against Colorectal Cancer Models
- Development of new preclinical models to advance adrenocortical carcinoma research
- An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function
- Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma